

ASX ANNOUNCEMENT

28 February 2024

Results of Rights Issue and Placement Update

HeraMED Limited (**ASX:HMD**) (**HMD** or **the Company**) advises that the pro rata entitlement offer to eligible shareholders (**Rights Issue**) closed at 5.00pm (Melbourne time) on 23 February 2024. The Rights issue was made on the basis of one fully paid ordinary share (**New Share**) for every five shares held by eligible shareholders (shareholders with a registered address in Australia or New Zealand at 7.00pm (Melbourne time) on 23 January 2024) (**Record Date**) at \$0.02 (2 cents) per New Share.

The Company advises it has received valid acceptances (including shortfall applications) from eligible shareholders for 11,235,627 New Shares (\$224,712.54) under the Rights Issue. The securities the subject of valid acceptances from eligible shareholders are to be issued today, 28 February 2024.

The Board thanks shareholders for the support they provided in participating in the Rights Issue.

The shortfall of the Rights Issue is 53,017,212 New Shares (\$1,060,344.25). As set out in the offer booklet for the Rights Issue released to ASX on 18 January 2024, HMD reserves the right to offer and issue New Shares from the shortfall at its discretion within three months after the closing date. To date the Company has received indicative offers for the balance of the shortfall from new investors and existing shareholders including the Company's Executive Chairman, Dr Ron Weinberger, who has received shareholder approval to subscribe for up to \$500,000 in the placement of shortfall shares. It is the Company's intention to conclude the placement of shortfall shares as quickly as possible. If there are any further shareholders who meet the sophisticated investors requirements under s.708 of the Corporations Act that are interested in participating please make contact with the Company.

The Company is also pleased to advise that shareholders approved all resolutions put to the general meeting on 23 February 2024, including approval for the issue of 20,750,000 ordinary shares at \$0.02 per share (\$415,000 in aggregate) under the second tranche of the placement announced to ASX on 15 December 2023. The Company anticipates issuing these shares forming the second tranche of the placement in the coming days.

-ENDS-

This announcement has been authorised by the Board of HeraMED Limited.

HeraMED Limited

Executive Chairman
Dr Ron Weinberger
M: +61 406 384 189
E: ron@hera-med.com

Company Secretary

Jonathan Hart
E: Jonathan@hera-med.com

Investor Relations

Tim Chapman
T: +61 419 897 062
E: tchapman@claritycap.com.au

About HeraMED Limited (ASX:HMD):

HeraMED is an innovative medical data and technology company leading the digital transformation of maternity care by revolutionising the prenatal and postpartum experience with its hybrid maternity care platform. HeraMED offers a proprietary platform that utilises hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence, and big data.

The Company's proprietary offering, HeraCARE, has been engineered to offer a fully integrated maternal health ecosystem designed to deliver better care at a lower cost, ensure expectant mothers are engaged, informed and well-supported, allow healthcare professionals to provide the highest quality care and enable early detection and prevention of potential risks.